Phase II trials were conducted by Mackiewicz et al. (2012) to determine the efficacy and toxicity of adjuvant treatment using the Hyper-IL-6 gene-modified whole-cell allogeneic melanoma vaccine in patients with stage 3 and 4 resected diseases [50]. The gene discussed is IL6; the disease is melanoma.